Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 174 entries
Sorted by: Best Match Show Resources per page
Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects.

Iranian journal of cancer prevention

Ghaderi B, Amini S, Maroofi F, Jalali C, Javanmardi M, Roshani D, Abdi M.
PMID: 27703646
Iran J Cancer Prev. 2016 Jun 13;9(3):e5069. doi: 10.17795/ijcp-5069. eCollection 2016 Jun.

BACKGROUND: B cell chronic lymphocytic leukemia is one of the most frequent hematologic malignancies in the world. Cellular surface CD markers and serum Beta-2-microglobulin may be used as a prognostic tool in CLL patients.OBJECTIVES: In the present study we...

Cite
Ghaderi B, Amini S, Maroofi F, et al. Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects. Iran J Cancer Prev. 2016;9(3):e5069doi: 10.17795/ijcp-5069.
Ghaderi, B., Amini, S., Maroofi, F., Jalali, C., Javanmardi, M., Roshani, D., & Abdi, M. (2016). Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects. Iranian journal of cancer prevention, 9(3), e5069. https://doi.org/10.17795/ijcp-5069
Ghaderi, Bayazid, et al. "Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects." Iranian journal of cancer prevention vol. 9,3 (2016): e5069. doi: https://doi.org/10.17795/ijcp-5069
Ghaderi B, Amini S, Maroofi F, Jalali C, Javanmardi M, Roshani D, Abdi M. Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects. Iran J Cancer Prev. 2016 Jun 13;9(3):e5069. doi: 10.17795/ijcp-5069. eCollection 2016 Jun. PMID: 27703646; PMCID: PMC5038830.
Copy Download .nbib Format: NLM
Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges.

Alzheimer's & dementia (Amsterdam, Netherlands)

O'Bryant SE, Lista S, Rissman RA, Edwards M, Zhang F, Hall J, Zetterberg H, Lovestone S, Gupta V, Graff-Radford N, Martins R, Jeromin A, Waring S, Oh E, Kling M, Baker LD, Hampel H.
PMID: 27019866
Alzheimers Dement (Amst). 2015 Dec 29;3:27-34. doi: 10.1016/j.dadm.2015.12.003. eCollection 2016.

INTRODUCTION: This study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms.METHODS: Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via...

Cite
O'Bryant SE, Lista S, Rissman RA, et al. Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimers Dement (Amst). 2015;3:27-34doi: 10.1016/j.dadm.2015.12.003.
O'Bryant, S. E., Lista, S., Rissman, R. A., Edwards, M., Zhang, F., Hall, J., Zetterberg, H., Lovestone, S., Gupta, V., Graff-Radford, N., Martins, R., Jeromin, A., Waring, S., Oh, E., Kling, M., Baker, L. D., & Hampel, H. (2016). Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimer's & dementia (Amsterdam, Netherlands), 327-34. https://doi.org/10.1016/j.dadm.2015.12.003
O'Bryant, Sid E, et al. "Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 3 (2016): 27-34. doi: https://doi.org/10.1016/j.dadm.2015.12.003
O'Bryant SE, Lista S, Rissman RA, Edwards M, Zhang F, Hall J, Zetterberg H, Lovestone S, Gupta V, Graff-Radford N, Martins R, Jeromin A, Waring S, Oh E, Kling M, Baker LD, Hampel H. Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimers Dement (Amst). 2015 Dec 29;3:27-34. doi: 10.1016/j.dadm.2015.12.003. eCollection 2016. PMID: 27019866; PMCID: PMC4802360.
Copy Download .nbib Format: NLM
Evaluation of salivary beta-2 microglobulin as HBV proliferation marker in HBS Ag(+), HBV DNA PCR(+) and HBV DNA PCR(-) subjects.

Gastroenterology and hepatology from bed to bench

Abdolsamadi H, Eini P, Ronasi N, Kaboli SA, Hajilooei M, MoghimBeigi A, Davoudi P, AhmadiMotemayel F, Shalmani HM.
PMID: 24834278
Gastroenterol Hepatol Bed Bench. 2013;6:S105-11.

AIM: The aim of this study was to determine the concentration of salivary B2M as a marker of viral proliferation in HBS Ag(+), HBV DNA PCR(+) and Hbs Ag(+) and HBV DNA PCR(-) subjects.BACKGROUND: Beta-2 microglobulin (B2M) is responsible...

Cite
Abdolsamadi H, Eini P, Ronasi N, et al. Evaluation of salivary beta-2 microglobulin as HBV proliferation marker in HBS Ag(+), HBV DNA PCR(+) and HBV DNA PCR(-) subjects. Gastroenterol Hepatol Bed Bench. 2013;6:S105-11
Abdolsamadi, H., Eini, P., Ronasi, N., Kaboli, S. A., Hajilooei, M., MoghimBeigi, A., Davoudi, P., AhmadiMotemayel, F., & Shalmani, H. M. (2013). Evaluation of salivary beta-2 microglobulin as HBV proliferation marker in HBS Ag(+), HBV DNA PCR(+) and HBV DNA PCR(-) subjects. Gastroenterology and hepatology from bed to bench, 6S105-11.
Abdolsamadi, Hamidreza, et al. "Evaluation of salivary beta-2 microglobulin as HBV proliferation marker in HBS Ag(+), HBV DNA PCR(+) and HBV DNA PCR(-) subjects." Gastroenterology and hepatology from bed to bench vol. 6 (2013): S105-11.
Abdolsamadi H, Eini P, Ronasi N, Kaboli SA, Hajilooei M, MoghimBeigi A, Davoudi P, AhmadiMotemayel F, Shalmani HM. Evaluation of salivary beta-2 microglobulin as HBV proliferation marker in HBS Ag(+), HBV DNA PCR(+) and HBV DNA PCR(-) subjects. Gastroenterol Hepatol Bed Bench. 2013;6:S105-11. PMID: 24834278; PMCID: PMC4017546.
Copy Download .nbib Format: NLM
Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences

Azenabor A, Ogbera AO, Adejumo NE, Adejare AO.
PMID: 22973323
J Res Med Sci. 2011 Oct;16(10):1298-305.

BACKGROUND: Acute Phase Reactants (APRs) have a wide range of activities that contribute to host defense. The aim of this report was to evaluate the dynamics and magnitude of these proteins in various microvascular complications in diabetes mellitus (DM)....

Cite
Azenabor A, Ogbera AO, Adejumo NE, et al. Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus. J Res Med Sci. 2011;16(10):1298-305
Azenabor, A., Ogbera, A. O., Adejumo, N. E., & Adejare, A. O. (2011). Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 16(10), 1298-305.
Azenabor, Alfred, et al. "Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus." Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences vol. 16,10 (2011): 1298-305.
Azenabor A, Ogbera AO, Adejumo NE, Adejare AO. Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus. J Res Med Sci. 2011 Oct;16(10):1298-305. PMID: 22973323; PMCID: PMC3430019.
Copy Download .nbib Format: NLM
X: beta 2 microglobulin and dialysis-associated amyloidosis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

[No authors listed]
PMID: 10978459
Nephrol Dial Transplant. 2000 Sep;15(9):A225-6.

No abstract available.

Cite
X: beta 2 microglobulin and dialysis-associated amyloidosis. Nephrol Dial Transplant. 2000;15(9):A225-6
(2000). X: beta 2 microglobulin and dialysis-associated amyloidosis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 15(9), A225-6.
"X: beta 2 microglobulin and dialysis-associated amyloidosis." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association vol. 15,9 (2000): A225-6.
X: beta 2 microglobulin and dialysis-associated amyloidosis. Nephrol Dial Transplant. 2000 Sep;15(9):A225-6. PMID: 10978459.
Copy Download .nbib Format: NLM
Phase I-II study of gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma.

Cancer biotherapy & radiopharmaceuticals

DeLima M, Amato RJ, Jackson A, Tu SM, Banks M, Finn L, Ellerhorst J.
PMID: 10851489
Cancer Biother Radiopharm. 1997 Dec;12(6):365-70. doi: 10.1089/cbr.1997.12.365.

We have completed a phase I/II trial to evaluate the toxicity and efficacy of the combination of gamma interferon and 5-fluorouracil in metastatic renal cell carcinoma. Gamma interferon was administered at a weekly dose of 100 micrograms. 5-fluorouracil was...

Cite
DeLima M, Amato RJ, Jackson A, et al. Phase I-II study of gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma. Cancer Biother Radiopharm. 1997;12(6):365-70doi: 10.1089/cbr.1997.12.365.
DeLima, M., Amato, R. J., Jackson, A., Tu, S. M., Banks, M., Finn, L., & Ellerhorst, J. (1997). Phase I-II study of gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma. Cancer biotherapy & radiopharmaceuticals, 12(6), 365-70. https://doi.org/10.1089/cbr.1997.12.365
DeLima, et al. "Phase I-II study of gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma." Cancer biotherapy & radiopharmaceuticals vol. 12,6 (1997): 365-70. doi: https://doi.org/10.1089/cbr.1997.12.365
DeLima M, Amato RJ, Jackson A, Tu SM, Banks M, Finn L, Ellerhorst J. Phase I-II study of gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma. Cancer Biother Radiopharm. 1997 Dec;12(6):365-70. doi: 10.1089/cbr.1997.12.365. PMID: 10851489.
Copy Download .nbib Format: NLM
beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Vassilakopoulos TP, Nadali G, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Karkantaris C, Kokoris SI, Dimitriadou EM, Calpadaki C, Sarantopoulos A, Galani Z, Sachanas S, Kyrtsonis MC, Tsaftaridis P, Variamis E, Panayotidis P, Pizzolo G, Sarris AH, Pangalis GA.
PMID: 17335133
J BUON. 2005 Jan-Mar;10(1):59-69.

PURPOSE: Serum beta-2 microglobulin (sbeta(2)m) is an established prognostic factor for several lymphoproliferative disorders. Because its significance in Hodgkin's lymphoma (HL) is controversial, we determined sbeta(2)m levels in pretreatment serum samples of patients with HL in order to elucidate...

Cite
Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. J BUON. 2005;10(1):59-69
Vassilakopoulos, T. P., Nadali, G., Angelopoulou, M. K., Dimopoulou, M. N., Siakantaris, M. P., Kontopidou, F. N., Karkantaris, C., Kokoris, S. I., Dimitriadou, E. M., Calpadaki, C., Sarantopoulos, A., Galani, Z., Sachanas, S., Kyrtsonis, M. C., Tsaftaridis, P., Variamis, E., Panayotidis, P., Pizzolo, G., Sarris, A. H., & Pangalis, G. A. (2005). beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 10(1), 59-69.
Vassilakopoulos, T P, et al. "beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens." Journal of B.U.ON. : official journal of the Balkan Union of Oncology vol. 10,1 (2005): 59-69.
Vassilakopoulos TP, Nadali G, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Karkantaris C, Kokoris SI, Dimitriadou EM, Calpadaki C, Sarantopoulos A, Galani Z, Sachanas S, Kyrtsonis MC, Tsaftaridis P, Variamis E, Panayotidis P, Pizzolo G, Sarris AH, Pangalis GA. beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. J BUON. 2005 Jan-Mar;10(1):59-69. PMID: 17335133.
Copy Download .nbib Format: NLM
Clinical value of new staging systems for multiple myeloma.

Cancer research and treatment

Choi JH, Yoon JH, Yang SK.
PMID: 19746184
Cancer Res Treat. 2007 Dec;39(4):171-4. doi: 10.4143/crt.2007.39.4.171. Epub 2007 Dec 31.

PURPOSE: We wanted to investigate the validity of the recently introduced Southwest Oncology Group (SWOG) staging system and the International Staging System (ISS) by comparing both systems with the widely accepted Durie/Salmon (DS) system for multiple myeloma patients.MATERIALS AND...

Cite
Choi JH, Yoon JH, Yang SK. Clinical value of new staging systems for multiple myeloma. Cancer Res Treat. 2007;39(4):171-4doi: 10.4143/crt.2007.39.4.171.
Choi, J. H., Yoon, J. H., & Yang, S. K. (2007). Clinical value of new staging systems for multiple myeloma. Cancer research and treatment, 39(4), 171-4. https://doi.org/10.4143/crt.2007.39.4.171
Choi, Jung-Hye, et al. "Clinical value of new staging systems for multiple myeloma." Cancer research and treatment vol. 39,4 (2007): 171-4. doi: https://doi.org/10.4143/crt.2007.39.4.171
Choi JH, Yoon JH, Yang SK. Clinical value of new staging systems for multiple myeloma. Cancer Res Treat. 2007 Dec;39(4):171-4. doi: 10.4143/crt.2007.39.4.171. Epub 2007 Dec 31. PMID: 19746184; PMCID: PMC2739370.
Copy Download .nbib Format: NLM
Daily (quotidian) nocturnal home hemodialysis: nine years later.

Hemodialysis international. International Symposium on Home Hemodialysis

Pierratos A.
PMID: 19379401
Hemodial Int. 2004 Jan 01;8(1):45-50. doi: 10.1111/j.1492-7535.2004.00074.x.

Daily nocturnal home hemodialysis was developed to satisfy the need for a highly effective, smooth, and cost-effective home dialysis therapy. It combines the benefits of the following dialysis methods: long, frequent, and home hemodialysis. It provides a high dialysis...

Cite
Pierratos A. Daily (quotidian) nocturnal home hemodialysis: nine years later. Hemodial Int. 2004;8(1):45-50doi: 10.1111/j.1492-7535.2004.00074.x.
Pierratos, A. (2004). Daily (quotidian) nocturnal home hemodialysis: nine years later. Hemodialysis international. International Symposium on Home Hemodialysis, 8(1), 45-50. https://doi.org/10.1111/j.1492-7535.2004.00074.x
Pierratos, Andreas. "Daily (quotidian) nocturnal home hemodialysis: nine years later." Hemodialysis international. International Symposium on Home Hemodialysis vol. 8,1 (2004): 45-50. doi: https://doi.org/10.1111/j.1492-7535.2004.00074.x
Pierratos A. Daily (quotidian) nocturnal home hemodialysis: nine years later. Hemodial Int. 2004 Jan 01;8(1):45-50. doi: 10.1111/j.1492-7535.2004.00074.x. PMID: 19379401.
Copy Download .nbib Format: NLM
Serum Beta 2-microglobulin/cystatin C index: a useful biomarker in lupus nephritis?.

Nephron extra

Madureira Silva MV, Moscoso-Solorzano GT, Nishida SK, Mastroianni-Kirsztajn G.
PMID: 22811690
Nephron Extra. 2012 Jan;2(1):169-76. doi: 10.1159/000339643. Epub 2012 Jun 22.

BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with frequent flares. Our aim was to evaluate the beta 2-microglobulin/cystatin C (β2M/CysC) index versus other markers as a predictor factor for assessment of SLE reactivation.METHODS: We prospectively...

Cite
Madureira Silva MV, Moscoso-Solorzano GT, Nishida SK, et al. Serum Beta 2-microglobulin/cystatin C index: a useful biomarker in lupus nephritis?. Nephron Extra. 2012;2(1):169-76doi: 10.1159/000339643.
Madureira Silva, M. V., Moscoso-Solorzano, G. T., Nishida, S. K., & Mastroianni-Kirsztajn, G. (2012). Serum Beta 2-microglobulin/cystatin C index: a useful biomarker in lupus nephritis?. Nephron extra, 2(1), 169-76. https://doi.org/10.1159/000339643
Madureira Silva, Marcus Vinicius, et al. "Serum Beta 2-microglobulin/cystatin C index: a useful biomarker in lupus nephritis?." Nephron extra vol. 2,1 (2012): 169-76. doi: https://doi.org/10.1159/000339643
Madureira Silva MV, Moscoso-Solorzano GT, Nishida SK, Mastroianni-Kirsztajn G. Serum Beta 2-microglobulin/cystatin C index: a useful biomarker in lupus nephritis?. Nephron Extra. 2012 Jan;2(1):169-76. doi: 10.1159/000339643. Epub 2012 Jun 22. PMID: 22811690; PMCID: PMC3398817.
Copy Download .nbib Format: NLM
Validation of reference genes for RT-qPCR analysis of CYP4T expression in crucian carp.

Genetics and molecular biology

Mo F, Zhao J, Liu N, Cao LH, Jiang SX.
PMID: 25249772
Genet Mol Biol. 2014 Sep;37(3):500-7. doi: 10.1590/s1415-47572014000400005.

Reference genes are commonly used for normalization of target gene expression during RT-qPCR analysis. However, no housekeeping genes or reference genes have been identified to be stable across different tissue types or under different experimental conditions. To identify the...

Cite
Mo F, Zhao J, Liu N, et al. Validation of reference genes for RT-qPCR analysis of CYP4T expression in crucian carp. Genet Mol Biol. 2014;37(3):500-7doi: 10.1590/s1415-47572014000400005.
Mo, F., Zhao, J., Liu, N., Cao, L. H., & Jiang, S. X. (2014). Validation of reference genes for RT-qPCR analysis of CYP4T expression in crucian carp. Genetics and molecular biology, 37(3), 500-7. https://doi.org/10.1590/s1415-47572014000400005
Mo, Fei, et al. "Validation of reference genes for RT-qPCR analysis of CYP4T expression in crucian carp." Genetics and molecular biology vol. 37,3 (2014): 500-7. doi: https://doi.org/10.1590/s1415-47572014000400005
Mo F, Zhao J, Liu N, Cao LH, Jiang SX. Validation of reference genes for RT-qPCR analysis of CYP4T expression in crucian carp. Genet Mol Biol. 2014 Sep;37(3):500-7. doi: 10.1590/s1415-47572014000400005. PMID: 25249772; PMCID: PMC4171773.
Copy Download .nbib Format: NLM
Treatment options for high-risk chronic lymphocytic leukaemia.

Therapeutic advances in hematology

Hewamana S, Dearden C.
PMID: 23556086
Ther Adv Hematol. 2011 Jun;2(3):147-59. doi: 10.1177/2040620711404469.

Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in the Western world. The natural history of CLL is extremely variable with a survival time from initial diagnosis that ranges from 2 to more than 20 years....

Cite
Hewamana S, Dearden C. Treatment options for high-risk chronic lymphocytic leukaemia. Ther Adv Hematol. 2011;2(3):147-59doi: 10.1177/2040620711404469.
Hewamana, S., & Dearden, C. (2011). Treatment options for high-risk chronic lymphocytic leukaemia. Therapeutic advances in hematology, 2(3), 147-59. https://doi.org/10.1177/2040620711404469
Hewamana, Saman, and Dearden, Claire. "Treatment options for high-risk chronic lymphocytic leukaemia." Therapeutic advances in hematology vol. 2,3 (2011): 147-59. doi: https://doi.org/10.1177/2040620711404469
Hewamana S, Dearden C. Treatment options for high-risk chronic lymphocytic leukaemia. Ther Adv Hematol. 2011 Jun;2(3):147-59. doi: 10.1177/2040620711404469. PMID: 23556086; PMCID: PMC3573406.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 174 entries